UNITED THERAPEUTICS CORP (UTHR) Fundamental Analysis & Valuation

NASDAQ:UTHR • US91307C1027

Current stock price

564.81 USD
-5.46 (-0.96%)
At close:
564.23 USD
-0.58 (-0.1%)
After Hours:

This UTHR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. UTHR Profitability Analysis

1.1 Basic Checks

  • In the past year UTHR was profitable.
  • UTHR had a positive operating cash flow in the past year.
  • UTHR had positive earnings in each of the past 5 years.
  • In the past 5 years UTHR always reported a positive cash flow from operatings.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • The Return On Assets of UTHR (16.94%) is better than 95.94% of its industry peers.
  • With an excellent Return On Equity value of 18.81%, UTHR belongs to the best of the industry, outperforming 95.16% of the companies in the same industry.
  • UTHR has a better Return On Invested Capital (16.10%) than 96.13% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for UTHR is significantly below the industry average of 27.17%.
  • The 3 year average ROIC (15.88%) for UTHR is below the current ROIC(16.10%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROIC 16.1%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • UTHR has a Profit Margin of 41.94%. This is amongst the best in the industry. UTHR outperforms 97.49% of its industry peers.
  • In the last couple of years the Profit Margin of UTHR has grown nicely.
  • UTHR has a better Operating Margin (47.63%) than 99.42% of its industry peers.
  • UTHR's Operating Margin has improved in the last couple of years.
  • UTHR has a better Gross Margin (87.92%) than 89.36% of its industry peers.
  • In the last couple of years the Gross Margin of UTHR has remained more or less at the same level.
Industry RankSector Rank
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. UTHR Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTHR is creating some value.
  • The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
  • The number of shares outstanding for UTHR has been reduced compared to 5 years ago.
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 21.99 indicates that UTHR is not in any danger for bankruptcy at the moment.
  • UTHR has a better Altman-Z score (21.99) than 89.75% of its industry peers.
  • There is no outstanding debt for UTHR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 21.99
ROIC/WACC1.75
WACC9.22%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • UTHR has a Current Ratio of 6.60. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.60, UTHR is in the better half of the industry, outperforming 65.38% of the companies in the same industry.
  • UTHR has a Quick Ratio of 6.28. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
  • UTHR's Quick ratio of 6.28 is fine compared to the rest of the industry. UTHR outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 6.28
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTHR Growth Analysis

3.1 Past

  • UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.41%, which is quite good.
  • Measured over the past years, UTHR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.23% on average per year.
  • Looking at the last year, UTHR shows a quite strong growth in Revenue. The Revenue has grown by 10.61% in the last year.
  • Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%

3.2 Future

  • Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.97% on average per year.
  • The Revenue is expected to grow by 11.61% on average over the next years. This is quite good.
EPS Next Y7.05%
EPS Next 2Y9.44%
EPS Next 3Y9.73%
EPS Next 5Y10.97%
Revenue Next Year4.32%
Revenue Next 2Y8.71%
Revenue Next 3Y10.39%
Revenue Next 5Y11.61%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

6

4. UTHR Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 20.24, the valuation of UTHR can be described as rather expensive.
  • UTHR's Price/Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 93.42% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.60, UTHR is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 18.91, which indicates a rather expensive current valuation of UTHR.
  • Based on the Price/Forward Earnings ratio, UTHR is valued cheaper than 94.78% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.84, UTHR is valued at the same level.
Industry RankSector Rank
PE 20.24
Fwd PE 18.91
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaper than 94.97% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 94.39% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 23.91
EV/EBITDA 12.78
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.87
PEG (5Y)1.05
EPS Next 2Y9.44%
EPS Next 3Y9.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTHR Dividend Analysis

5.1 Amount

  • UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTHR Fundamentals: All Metrics, Ratios and Statistics

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (4/2/2026, 8:00:02 PM)

After market: 564.23 -0.58 (-0.1%)

564.81

-5.46 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners98.05%
Inst Owner Change1.2%
Ins Owners1.81%
Ins Owner Change32.81%
Market Cap24.76B
Revenue(TTM)3.18B
Net Income(TTM)1.33B
Analysts81.9
Price Target603.09 (6.78%)
Short Float %6.63%
Short Ratio5.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.35%
Min EPS beat(2)-2.35%
Max EPS beat(2)5.05%
EPS beat(4)1
Avg EPS beat(4)-1.8%
Min EPS beat(4)-9.46%
Max EPS beat(4)5.05%
EPS beat(8)2
Avg EPS beat(8)-2.1%
EPS beat(12)6
Avg EPS beat(12)0.77%
EPS beat(16)8
Avg EPS beat(16)-0.29%
Revenue beat(2)0
Avg Revenue beat(2)-4.27%
Min Revenue beat(2)-4.72%
Max Revenue beat(2)-3.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)6.71%
Revenue beat(8)4
Avg Revenue beat(8)0.39%
Revenue beat(12)7
Avg Revenue beat(12)1.48%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)10.29%
PT rev (3m)15.94%
EPS NQ rev (1m)-3.11%
EPS NQ rev (3m)-3.83%
EPS NY rev (1m)1.35%
EPS NY rev (3m)0.38%
Revenue NQ rev (1m)-1.31%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)-1.39%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 20.24
Fwd PE 18.91
P/S 7.78
P/FCF 23.91
P/OCF 15.86
P/B 3.49
P/tB 3.55
EV/EBITDA 12.78
EPS(TTM)27.9
EY4.94%
EPS(NY)29.87
Fwd EY5.29%
FCF(TTM)23.62
FCFY4.18%
OCF(TTM)35.62
OCFY6.31%
SpS72.61
BVpS161.9
TBVpS159.25
PEG (NY)2.87
PEG (5Y)1.05
Graham Number318.8
Profitability
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROCE 20.71%
ROIC 16.1%
ROICexc 26.8%
ROICexgc 27.52%
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
FCFM 32.53%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
ROICexc(3y)29.26%
ROICexc(5y)26.59%
ROICexgc(3y)30.21%
ROICexgc(5y)27.3%
ROCE(3y)20.42%
ROCE(5y)18.56%
ROICexgc growth 3Y0.25%
ROICexgc growth 5Y6.53%
ROICexc growth 3Y-0.12%
ROICexc growth 5Y7.38%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
F-Score8
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 614.49%
Cap/Sales 16.53%
Interest Coverage 112.28
Cash Conversion 97.49%
Profit Quality 77.56%
Current Ratio 6.6
Quick Ratio 6.28
Altman-Z 21.99
F-Score8
WACC9.22%
ROIC/WACC1.75
Cap/Depr(3y)462.52%
Cap/Depr(5y)380.04%
Cap/Sales(3y)11.66%
Cap/Sales(5y)9.87%
Profit Quality(3y)81.3%
Profit Quality(5y)87.1%
High Growth Momentum
Growth
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
EPS Next Y7.05%
EPS Next 2Y9.44%
EPS Next 3Y9.73%
EPS Next 5Y10.97%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%
Revenue Next Year4.32%
Revenue Next 2Y8.71%
Revenue Next 3Y10.39%
Revenue Next 5Y11.61%
EBIT growth 1Y4.68%
EBIT growth 3Y15.26%
EBIT growth 5Y20.65%
EBIT Next Year11.69%
EBIT Next 3Y9.49%
EBIT Next 5Y-7.27%
FCF growth 1Y-4.2%
FCF growth 3Y15.97%
FCF growth 5Y8.25%
OCF growth 1Y17.64%
OCF growth 3Y24.84%
OCF growth 5Y15.62%

UNITED THERAPEUTICS CORP / UTHR Fundamental Analysis FAQ

What is the fundamental rating for UTHR stock?

ChartMill assigns a fundamental rating of 7 / 10 to UTHR.


What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?

ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.


How profitable is UNITED THERAPEUTICS CORP (UTHR) stock?

UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for UTHR stock?

The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 20.24 and the Price/Book (PB) ratio is 3.49.